A pet healthcare product and a preparation method and application thereof

Abstract

This application relates to the field of pet food technology, specifically disclosing a pet health supplement, its preparation method, and its application. The pet health supplement, by weight, comprises the following raw material components: 60-90 parts hydrolyzed small molecule protein peptides; 0.1-1 part chicken egg-derived IgY antibody; 0.1-1 part natural organic acid; 1-5 parts glycerol; 0.1-1 part natural antioxidants; 0.5-5 parts prebiotics; 0-0.05 parts ε-polylysine; and 1-15 parts functional ingredients. The pet health supplement of this application can effectively reduce the risk of allergies in pets and people in contact with them, and is safe and non-toxic with good palatability and flavor, suitable for long-term feeding to pets.

Description

Technical Field

[0001] This application belongs to the field of pet food technology, specifically relating to a pet health product, its preparation method, and its application. Background Technology

[0002] With accelerated urbanization and changes in family structure, pet ownership is experiencing a continuous growth trend globally. Accompanying this is a rising incidence of pet allergies. It is estimated that approximately 20% of the world's population is allergic to cats and dogs. Besides mild symptoms such as sneezing and runny nose, pet allergies can trigger severe allergic rhinitis, asthma, atopic dermatitis, and urticaria, significantly impacting the quality of life of affected cats and dogs.

[0003] Pet allergies include environmental allergies and food allergies. Food allergies, in particular, have become a common problem affecting the health and quality of life of companion animals. Clinical observations show that skin problems account for over 60% of cases seen in veterinary clinics, a significant portion of which are related to food allergies. Unlike allergies caused by environmental allergens (such as pollen and dust mites), food allergies stem from an abnormal immune response to specific food components. This response can occur at any stage of a pet's life, and even a long-term allergy can suddenly develop. In recent years, dietary management strategies for pet allergies have made significant progress. From traditional hydrolyzed protein diets to novel insect protein sources, from single nutritional supplements to comprehensive gut-skin axis regulation, nutritional intervention strategies are becoming increasingly diverse and refined.

[0004] Pet food allergens are primarily proteins or peptides with large molecular weights and stable structures. Studies have shown that allergic reactions in dogs and cats to different protein sources exhibit certain patterns. Beef and dairy products are the most common allergens in dogs and cats, with beef accounting for 34% of allergens in both species. Other common allergens include wheat, chicken, eggs, lamb, soy, corn, pork, and fish. It is also worth noting that pets may be allergic to multiple food components simultaneously, and the distribution of allergens varies by species and region.

[0005] Currently, almost all pet foods contain ingredients from various sources, including meat, eggs, seafood, grains, and vegetables. The proteins in these foods are highly likely to be allergens, triggering allergic reactions. Although newer proteins such as insect protein, crocodile protein, and turtle protein have become preferred as low-allergenic options in recent years, this is because the pet's immune system cannot yet recognize these new allergens. Long-term feeding still carries the risk of allergic reactions. Especially with mainstream commercially available health supplements (such as Red Dog, Weishi, Medex, Viyo, and MAG), while they provide nutritional supplements, the allergens they contain inevitably pose an allergy risk to both healthy and allergy-prone pets—a significant health concern. Furthermore, some people are also allergic to Fel d1, a major allergen in cat saliva and sebaceous gland secretions, which inevitably affects the harmonious coexistence of pets and humans. Therefore, developing a pet health supplement suitable for long-term pet consumption, without toxic side effects, and possessing both low allergenicity for pets and low allergen levels, while also reducing the allergy risk for pet owners, is a pressing technical problem that needs to be solved. Summary of the Invention

[0006] The purpose of this application is to provide a pet health product, its preparation method, and its application, in order to solve the problem that existing pet health products are sensitizing to both pets and people who come into contact with the pets.

[0007] In order to achieve the above-mentioned purpose, firstly, this application provides a pet health product.

[0008] The pet health product, by weight, comprises the following raw material components: 60-90 parts of hydrolyzed small molecule protein peptides; Chicken egg-derived IgY antibody 0.1-1 part; 0.1 to 1 part of natural organic acids; 1-5 parts of glycerol; 0.1 to 1 part of natural antioxidants; Prebiotics 0.5-5 servings; 0-0.05 parts of ε-polylysine; Functional ingredients: 1-15 parts.

[0009] In some embodiments, the average molecular weight of the hydrolyzed small molecule protein peptides is 800 Da to 1500 Da; and / or, The functional ingredients include at least one of the following: polysaccharides, dietary fiber, polyphenols, functional lipids, minerals, vitamins, enzymes, plant active ingredients, peptides and proteins, and lactic acid bacteria.

[0010] In some embodiments, the chicken egg-derived IgY antibody is selected from egg yolk immunoglobulins produced after immunization of hens with Feld1 protein; and / or, The natural organic acid is selected from at least one of malic acid, citric acid, lactic acid, and tartaric acid.

[0011] In some embodiments, the prebiotic is selected from at least one of liquid galactooligosaccharides, liquid fructooligosaccharides, liquid isomaltooligosaccharides, and liquid xylooligosaccharides; and / or, The natural antioxidant is selected from at least one of vitamin C and its derivatives, vitamin E and its derivatives, astaxanthin, and rosemary extract.

[0012] Secondly, this application provides a method for preparing a pet health product, comprising the following steps: Hydrolyzed small molecule protein peptides, glycerol, prebiotics and natural organic acids are homogenized and emulsified in water to obtain the first material. The first material is sterilized to obtain the second material; At room temperature, natural antioxidants, chicken egg-derived IgY antibodies, ε-polylysine and functional ingredients are added to the second material and mixed well to obtain the third material. The third material is concentrated and molded under vacuum conditions at 55~60℃ to obtain a pet health product.

[0013] In some embodiments, the homogenization emulsification temperature is 45°C to 50°C; and / or, During emulsification, the rotation speed is between 3000 r / min and 10000 r / min.

[0014] In some embodiments, the homogenization emulsification is performed at a frequency of once every 15 minutes of homogenization followed by vacuuming, and the homogenization emulsification is repeated 2 to 5 times, with the number of vacuuming processes being the same as the number of homogenization emulsification processes; and / or, The homogenization emulsification was carried out under conditions of -0.08 to -0.07 MPa.

[0015] In some embodiments, the sterilization process is carried out at a temperature of 90-95°C for 10-15 minutes; and / or, After the sterilization process, the temperature is lowered to 55~60℃.

[0016] In some embodiments, the vacuum degree of the concentration process is -0.08 to -0.07 MPa; and / or, After concentration and molding, the moisture content of the product is 35-40%.

[0017] Thirdly, this application provides the application of the pet health care products described in any one of the above claims or the pet health care products prepared by the preparation method described in any one of the above claims in the preparation of hypoallergenic pet products.

[0018] Compared to existing technologies, the pet health product of this application uses hydrolyzed small molecule protein peptides as its main component, replacing common allergenic protein sources such as meat, eggs, seafood, grains, and fruits and vegetables. This pet health product has a pleasant, palatable flavor that pets love. Simultaneously, the hydrolyzed small molecule protein peptides, combined with chicken egg-derived IgY, prebiotics, and other functional ingredients, can significantly reduce the allergy risk for both pets and people in contact with them. Animal studies have verified that the pet health product prepared according to this invention effectively reduces allergic reactions, is safe and non-toxic, has good palatability, and can be consumed long-term. Attached Figure Description

[0019] To make the objectives, technical solutions, and advantages of the present invention clearer, the preferred embodiments of the present invention will be described in detail below with reference to the accompanying drawings, wherein: Figure 1 This is a bar chart showing the antigenicity of pets assessed using the ELISA assessment™ method in this application; Figure 2 This is a graph showing the test results of pet skin moisture, oil, elasticity and pH in this application; Figure 3 This is a graph showing the scoring results for the pet's lameness in this application; Figure 4 The images show the X-ray and CT scan results of the pet's lameness as described in this application. Detailed Implementation

[0020] To make the technical problems, technical solutions, and beneficial effects of this application clearer, the following detailed description is provided in conjunction with embodiments. It should be understood that the specific embodiments described herein are merely illustrative and not intended to limit the scope of this application.

[0021] In this application, the term "and / or" describes the relationship between related objects, indicating that three relationships can exist. For example, A and / or B can represent: A existing alone, A and B existing simultaneously, or B existing alone. A and B can be singular or plural. The character " / " generally indicates that the preceding and following related objects have an "or" relationship.

[0022] In this application, "at least one" means one or more, and "more than one" means two or more. "At least one of the following" or similar expressions refer to any combination of these items, including any combination of single or multiple items. For example, "at least one of a, b, or c", or "at least one of a, b, and c", can both mean: a, b, c, ab (i.e., a and b), ac, bc, or abc, where a, b, and c can be single or multiple.

[0023] It should be understood that in the various embodiments of this application, the order of the above processes does not imply the order of execution. Some or all steps may be executed in parallel or sequentially. The execution order of each process should be determined by its function and internal logic, and should not constitute any limitation on the implementation process of the embodiments of this application.

[0024] The terminology used in the embodiments of this application is for the purpose of describing particular embodiments only and is not intended to be limiting of this application. The singular forms “a,” “the,” and “the” used in the embodiments of this application and the appended claims are also intended to include the plural forms unless the context clearly indicates otherwise.

[0025] The weights of the relevant components mentioned in the embodiments of this application can refer not only to the specific content of each component, but also to the proportional relationship between the weights of the components. Therefore, any scaling up or down of the content of the relevant components according to the embodiments of this application is within the scope disclosed in the embodiments of this application. Specifically, the mass described in the embodiments of this application can be a well-known unit of mass in the chemical industry, such as µg, mg, g, or kg.

[0026] The terms "first" and "second" are used for descriptive purposes only, to distinguish objects, such as substances, from one another, and should not be construed as indicating or implying relative importance or implicitly specifying the number of technical features indicated. For example, without departing from the scope of the embodiments of this application, "first XX" may also be referred to as "second XX," and similarly, "second XX" may also be referred to as "first XX." Thus, features defined with "first" and "second" may explicitly or implicitly include one or more of that feature.

[0027] The pet health product provided in this embodiment of the invention comprises the following raw material components by weight: 60-90 parts of hydrolyzed small molecule protein peptides; Chicken egg-derived IgY antibody 0.1-1 part; 0.1 to 1 part of natural organic acids; 1-5 parts of glycerol; 0.1 to 1 part of natural antioxidants; Prebiotics 0.5-5 servings; 0-0.05 parts of ε-polylysine; Functional ingredients: 1-15 parts.

[0028] In some embodiments, the hydrolyzed small molecule protein peptides in pet health products can be in typical or atypical weight proportions such as 60 parts, 62 parts, 65 parts, 68 parts, 70 parts, 75 parts, 80 parts, 85 parts, or 90 parts, or any weight proportion between 60 and 90 parts. Because hydrolyzed small molecule protein peptides possess certain biological activities, adding them to pet health products is beneficial for promoting mineral absorption, anti-oxidation, anti-hypertensive effects, and immune regulation, playing an important role in the treatment of pet diseases. In some embodiments, the hydrolyzed small molecule protein peptides are derived from hydrolyzed small molecule proteins such as Antarctic krill protein peptides, collagen peptides, and fish lysate.

[0029] In some embodiments, the average molecular weight of the hydrolyzed small molecule protein peptide is 800-1500 Da. For example, the average molecular weight can be 850 Da, 880 Da, 900 Da, 920 Da, 950 Da, 960 Da, 980 Da, 990 Da, 1000 Da, 1020 Da, 1050 Da, 1060 Da, 1080 Da, 1120 Da, 1150 Da, 1180 Da, 1200 Da, 1250 Da, 1280 Da, 1300 Da, 1350 Da, 1380 Da, 1410 Da, 1450 Da, 1460 Da, 1470 Da, 1480 Da, 1490 Da, or 1500 Da, or any two of these average molecular weights. Hydrolyzed small molecule protein peptides with an average molecular weight within this range are rich in flavor substances, are not only easily digested and absorbed, but also do not have allergenic properties. As for bitter peptides, the average molecular weight range is 1000~6000 Da. In this embodiment, the cross-distribution of hydrolyzed small molecule protein peptides and bitter peptides in the molecular weight range not only makes the hydrolyzed small molecule protein peptides have a richer flavor substance, but also presents a better palatability. At the same time, it also avoids the impact of the presence of bitter peptides on the palatability of pets to a certain extent.

[0030] In some embodiments, the weight parts of chicken egg-derived IgY antibodies can be typical or atypical, such as 0.1 parts, 0.2 parts, 0.25 parts, 0.3 parts, 0.35 parts, 0.4 parts, 0.5 parts, 0.55 parts, 0.6 parts, 0.65 parts, 0.7 parts, 0.75 parts, 0.8 parts, 0.9 parts, 0.95 parts, or any weight part between 0.1 and 1 part. Chicken egg-derived IgY is derived from the yolk immunoglobulin produced after immunizing hens with Feld1 protein. This type of yolk immunoglobulin has unique biological characteristics, can tolerate amphoteric conditions of pH 4-11 and high temperatures of 65°C and above, and remains stable in the digestive tract environment. For example, when this pet health product is added to cat food and fed to cats, it can significantly improve the nasal symptom score of the recipient by specifically neutralizing Feld1 in the cat's saliva, especially significantly reducing nasal congestion. The effect was even more pronounced when fed to cats that already had high Feld1 secretion levels.

[0031] In some embodiments, the combination of natural organic acids and prebiotics not only provides pet health products with a sweet and sour taste that pets enjoy and stimulates their appetite, but also the natural organic acids have effects such as promoting digestion, lowering gastrointestinal pH, antibacterial activity, antioxidant properties, and chelating minerals. In some embodiments, the natural organic acid is selected from at least one of malic acid, citric acid, lactic acid, and tartaric acid.

[0032] In some implementations, glycerol, as a natural component, is mainly derived from palm fruit and has a sweet taste. It not only has moisturizing and plasticizing effects, but also helps to dissolve and evenly disperse other functional ingredients (such as vitamins, minerals, plant extracts, etc.), ensuring that these ingredients are more stable in the product and do not precipitate or separate.

[0033] In some embodiments, natural antioxidants can neutralize free radicals by inhibiting oxidation, thus not only mitigating the oxidation process of the product system and ensuring the product's shelf-life quality stability, but also possessing high functional nutritional value for the body. These functional nutritional values ​​mainly include free radical scavenging, anti-aging, immune enhancement, anti-inflammatory effects, and anti-oxidative stress. In some embodiments, the natural antioxidant is selected from at least one of vitamin C and its derivatives, vitamin E and its derivatives, astaxanthin (krill oil), and rosemary extract.

[0034] In some embodiments, prebiotics exert their anti-allergic effects by regulating the gut-skin axis. As "food" for probiotics, prebiotics help beneficial bacteria colonize and proliferate, promote gut microbiota balance, enhance intestinal barrier function, regulate the immune response towards Th1 / Treg, and inhibit excessive Th2 immune responses, thereby suppressing food allergies. Supplementation with specific probiotics and prebiotics can reduce the recurrence rate of allergies in pets by 52%. In some embodiments, the prebiotic is selected from at least one of liquid galactooligosaccharides, liquid fructooligosaccharides, liquid isomaltooligosaccharides, and liquid xylooligosaccharides.

[0035] In some implementations, ε-polylysine, as a natural antibacterial and preservative agent, has been widely used in human and pet food. In the human body, it is broken down into lysine monomers by proteases, which are then absorbed by the intestines and enter the bloodstream. Unutilized small molecule polylysine fragments can be filtered out of the body by the kidneys, and the metabolic mechanism is similar to that of ordinary proteins.

[0036] In some embodiments, the functional ingredients include at least one of polysaccharides, dietary fiber, polyphenols, functional lipids, minerals, vitamins, enzymes, plant-based active ingredients, peptides and proteins, and lactic acid bacteria. In some embodiments, the functional lipids include at least one of fats, lipids, and sterols. Lipids may be phospholipids, which not only improve the digestibility and absorption of fats and fat-soluble vitamins (such as vitamins A, D, E, and K) through emulsification, but also play an important role in pet coat and skin care, cardiovascular protection, immunity enhancement, and brain development.

[0037] Based on the above-mentioned pet health product formula, this embodiment of the invention also provides a method for preparing the pet health product.

[0038] Specifically, the preparation method of pet health products includes the following steps: S01. Hydrolyzed small molecule protein peptides, glycerol, prebiotics and natural organic acids are homogenized and emulsified in water to obtain the first material; S02. The first material is sterilized to obtain the second material; S03. At room temperature, add natural antioxidants, chicken egg-derived IgY antibody, ε-polylysine and functional ingredients to the second material, mix well, and obtain the third material. S04. The third material is concentrated and molded under vacuum conditions of 55~60℃ to obtain pet health products.

[0039] In some embodiments, the homogenization emulsification temperature is 45°C to 50°C, for example, 45°C, 46°C, 48°C, or 50°C. In some embodiments, stirring is required during emulsification, for example, continuous stirring can be performed at a stirring speed of 3000 r / min to 10000 r / min, and the stirring speed can be 3000 r / min, 3500 r / min, 3800 r / min, 3900 r / min, 4000 r / min, 4500 r / min, 5000 r / min, 5500 r / min, 6000 r / min, 6500 r / min, 7000 r / min, 7500 r / min, 8000 r / min, 8500 r / min, 9000 r / min, 10000 r / min, or any speed between any two speeds.

[0040] In some embodiments, the homogenization emulsification is performed with a vacuum cycle every 15 minutes of homogenization, and this process is repeated 2-5 times. The number of vacuum cycles is the same as the number of homogenization emulsification cycles; for example, homogenization emulsification twice followed by vacuum cycles; or homogenization emulsification three times followed by vacuum cycles; or homogenization emulsification four times followed by vacuum cycles. In some embodiments, the entire homogenization emulsification process is carried out under conditions of -0.08 to -0.07 MPa. Through homogenization emulsification, oil droplets are broken down into micron-sized particles, forming a uniform and stable emulsion, preventing subsequent stratification.

[0041] In some embodiments, the sterilization process is carried out at a temperature of 90-95°C for 10-15 minutes to kill pathogenic bacteria and most spoilage bacteria, while maximizing the protection of heat-sensitive nutrients (such as vitamins and prebiotics) from high-temperature degradation. In some embodiments, natural antioxidants, chicken egg-derived IgY antibodies, ε-polylysine, and functional components can be mixed and then mixed with the second material. After sterilization, the temperature is lowered to 55-60°C, and concentration is carried out under vacuum conditions at 55-60°C. The vacuum degree of the concentration process is -0.08 to -0.07 MPa. After the above concentration process, the moisture content of the product is 35-40%.

[0042] The pet health products obtained above can be used to prepare hypoallergenic pet products, thereby obtaining products that are hypoallergenic to pets, pet owners, and people who come into contact with pets. The obtained products can be used to feed dogs, cats, rodents, birds, etc.

[0043] The following examples illustrate the pet health products and other items described in this application.

[0044] Example 1 A pet health supplement comprises the following ingredients in parts by weight: 60 parts Antarctic krill protein peptides, 0.5 parts chicken egg-derived IgY antibody, 2 parts phospholipids (as a functional ingredient), 0.3 parts citric acid, 2 parts glycerol, 0.5 parts vitamin E, 0.5 parts fructooligosaccharides, and 0.02 parts ε-polylysine.

[0045] The preparation method of the pet health product includes the following steps: (1) Weigh out the corresponding components according to the above weight proportions and set aside.

[0046] (2) Add the specified amount of purified water to a mixing tank equipped with a stirrer and heat it to 45°C. Slowly add Antarctic krill protein peptides, glycerol, fructooligosaccharides and citric acid while stirring until completely dissolved to obtain an aqueous mixture.

[0047] (3) In another mixing tank, chicken egg source IgY antibody, ε-polylysine, phospholipids and vitamin E (natural antioxidant) are mixed, heated slightly to 35°C and stirred evenly to obtain an oil phase mixture.

[0048] (4) The oil phase mixture is slowly poured into the aqueous phase mixture being sheared at 3000 rpm in a thin stream. After initial mixing, a crude emulsion is obtained. It is then transferred to a high-shear homogenizer and homogenized and emulsified three times under a pressure of 30 MPa. Vacuum treatment is performed after each homogenization and emulsification.

[0049] (5) Transfer the homogenized emulsion to a mixing tank, cool it to below 40°C and stir continuously to ensure full dispersion, and finally add purified water to make up to the final volume.

[0050] (6) Vacuum degassing removes air bubbles introduced during stirring and homogenization emulsification to prevent oxidation and filling problems. After degassing is completed, filter with 100-mesh filter cloth to remove any trace impurities and insoluble particles that may exist.

[0051] (7) Automatic filling machine is used to fill in a Class 100,000 clean environment. The size is 10g / bag. After filling, nitrogen is immediately filled and sealed to minimize secondary pollution and oxidation.

[0052] (8) Use water bath pasteurization method and keep at 75℃ for 15 minutes.

[0053] (9) After sterilization, cool rapidly to room temperature, label and store in a cool, dry place, avoiding direct sunlight, and keep at a temperature of 20°C and a humidity of 40%.

[0054] Example 2 A pet health supplement comprises the following ingredients in parts by weight: 70 parts Antarctic krill protein peptides, 0.2 parts chicken egg-derived IgY antibody, 3 parts phospholipids, 0.1 parts natural organic acids, 1 part glycerol, 0.2 parts natural antioxidants, 0.3 parts fructooligosaccharides, 0.04 parts ε-polylysine, and 2 parts cellulose (functional ingredient).

[0055] The preparation method of the pet health product includes the following steps: (1) Weigh out the corresponding components according to the above weight proportions and set aside.

[0056] (2) Add the specified amount of purified water to a mixing tank equipped with a stirrer and heat it to 50°C. Slowly add hydrolyzed protein peptide powder, glycerol, fructooligosaccharides and citric acid while stirring until completely dissolved to obtain an aqueous mixture.

[0057] (3) In another mixing tank, chicken egg source IgY antibody, ε-polylysine, cellulose, phospholipids and vitamin E (natural antioxidant) are mixed, heated slightly to 40°C and stirred evenly to obtain an oil phase mixture.

[0058] (4) The oil phase mixture is slowly poured into the aqueous phase mixture under shear at 3000 rpm in a thin stream. After initial mixing, a crude emulsion is obtained and transferred to a high shear homogenizer for homogenization three times under a pressure of 35 MPa.

[0059] (5) Gentle mixing and volume adjustment: Transfer the homogenized emulsion to a mixing tank, cool it to below 40°C and stir continuously to ensure full dispersion. Finally, add deionized water to adjust the volume to the final volume.

[0060] (6) Vacuum degassing removes air bubbles introduced during stirring and homogenization to prevent oxidation and filling problems. After degassing is completed, filter with 150 mesh filter cloth to remove any trace impurities and insoluble particles that may exist.

[0061] (7) Automatic filling machine is used to fill in a Class 100,000 clean environment. The size is 10g / bag. After filling, nitrogen is immediately filled and sealed to minimize secondary pollution and oxidation.

[0062] (8) Use water bath pasteurization method and keep at 72℃ for 30 minutes.

[0063] (9) After sterilization, cool rapidly to room temperature, label and store in a cool, dry place, avoiding direct sunlight, at a temperature of 20°C and a humidity of 40%.

[0064] Example 3 A pet health supplement comprises the following ingredients in parts by weight: 90 parts hydrolyzed small molecule protein peptides, 0.5 parts chicken egg-derived IgY antibody, 4 parts phospholipids, 0.3 parts citric acid, 4 parts glycerol, 0.3 parts natural antioxidants, 0.03 parts ε-polylysine, 1 part fructooligosaccharide, and 5 parts fish oil.

[0065] The preparation method of the pet health product includes the following steps: (1) Weigh out the corresponding components according to the above weight proportions and set aside.

[0066] (2) In a mixing tank equipped with a stirrer, add the specified amount of purified water and heat to 45°C. While stirring, slowly add hydrolyzed protein peptide powder, glycerol, fructooligosaccharides and citric acid until completely dissolved to obtain an aqueous mixture.

[0067] (3) In another mixing tank, chicken egg source IgY antibody, ε-polylysine, fish oil, phospholipids and vitamin E (natural antioxidant) are mixed, heated slightly to 45°C and stirred evenly to obtain an oil phase mixture.

[0068] (4) The oil phase mixture is slowly poured into the aqueous phase mixture at 3000 rpm in a thin stream. After initial mixing, a crude emulsion is obtained. It is then transferred to a high-shear homogenizer and homogenized three times at a pressure of 30 MPa. After each homogenization and emulsification, a vacuum is applied once.

[0069] (5) Transfer the homogenized emulsion to a mixing tank, cool it to below 50°C and stir continuously to ensure full dispersion, and finally add purified water to make up to the final volume.

[0070] (6) Vacuum degassing to remove air bubbles introduced during stirring and homogenization. After degassing is complete, filter with a 100-mesh filter cloth.

[0071] (7) The automatic filling machine is used to fill the bag in a Class 100,000 clean environment. The bag is 10g in size and sealed with nitrogen immediately after filling.

[0072] (8) Use water bath pasteurization method and keep at 75℃ for 15 minutes.

[0073] (9) After sterilization, cool rapidly to room temperature, label and store in a cool, dry place, avoiding direct sunlight, at a temperature of 23°C and a humidity of 40%.

[0074] Example 4 A pet health supplement comprises the following ingredients in parts by weight: 80 parts hydrolyzed small molecule protein peptides, 1 part chicken egg-derived IgY antibody, 2 parts phospholipids, 0.2 parts natural organic acids, 2 parts glycerol, 0.3 parts natural antioxidants, 0.5 parts galactooligosaccharides, 0.04 parts ε-polylysine, and 10 parts glutamine.

[0075] The preparation method is the same as in Example 1, and will not be elaborated further here to save space.

[0076] Example 5 A pet health supplement comprises the following ingredients in parts by weight: 60 parts Antarctic krill protein peptide powder, 0.5 parts chicken egg-derived IgY antibody, 1 part phospholipid, 0.2 parts citric acid, 1 part glycerol, 0.2 parts vitamin E, 1 part fructooligosaccharide, 0.04 parts ε-polylysine, 2 parts fish oil, 2 parts glucosamine hydrochloride, and 1 part chondroitin sulfate.

[0077] The preparation method is the same as in Example 1, and will not be elaborated further here to save space.

[0078] Comparative Example 1 A pet health supplement comprises the following ingredients in parts by weight: 60 parts Antarctic krill protein peptide powder, 1 part phospholipid, 0.2 parts citric acid, 1 part glycerol, 0.2 parts vitamin E, 1 part fructooligosaccharide, 0.04 parts ε-polylysine, and 5 parts glutamine.

[0079] The preparation method is the same as in Example 1, and will not be elaborated further here to save space.

[0080] Animal safety testing of pet health products This study included 24 healthy adult bobtail cats, all over one week old, of similar weight, and roughly equal in sex. All cats had no history of immune-mediated diseases, were not allergic, and had no other diseases that could cause chronic gastrointestinal dysfunction, including liver disease, pancreatic insufficiency, metabolic diseases, parasitic diseases, and kidney diseases. The cats had not received any medications or diets related to the tested function within the past three months, had not used antibiotics, immunosuppressive drugs, or undergone surgery. Pregnant and lactating cats, and cats unable to eat orally, were excluded.

[0081] Twenty-four healthy adult bobtail cats were randomly assigned to three treatment groups, with half males and half females in each group: Example 1, Example 3, and Example 5. The control group was fed a regular diet. Example 1 group received an additional 160g of the pet supplement prepared in Example 1 daily on top of their regular diet. Example 3 group received an additional 160g of the pet supplement prepared in Example 3 daily on top of their regular diet. Example 5 group received an additional 160g of the pet supplement prepared in Example 5 daily on top of their regular diet. All cats were fed the same basal diet, the amount of which met the energy and nutritional needs of adult cats. Each treatment had eight replicates, with one cat per replicate. During the experiment, the general condition of each cat was observed during feeding, and any abnormalities were recorded. A five-day pre-feeding period was observed during which each cat refused to eat the basal diet or exhibited an abnormally reduced food intake. If any of these conditions occurred, the cat was excluded from the experiment. The formal trial period was 30 days. Body weight was measured and stool scores were performed on days 1, 5, 9, 13, 15, 19, 23, 27 and 30. Blood samples were collected on days 15 and 30 for hematological and blood biochemistry tests.

[0082] Weight gain test: The test cat was placed on a pet scale and the weight was taken after the scale stabilized. The results are shown in Tables 1-1, 1-2 and 1-3.

[0083] Table 1-1 Food intake, body weight, and fecal matter in the pre-feeding group of cats in Example 1 (n=8) ; Table 1-2 Food intake, body weight, and fecal matter in the pre-feeding group of cats in Example 3 (n=8) ; Table 1-3 Food intake, body weight, and fecal matter in the 5th group of test cats during the pre-feeding period (n=8) ; As shown in Tables 1-1, 1-2 and 1-3, on days 0, 15 and 30, the weight of groups 1, 3 and 5 increased slightly compared with the control group, but the difference was not significant, proving that the pet health care products of the present invention will not have a negative impact on the growth of pets.

[0087] Hematological parameters were measured using an automated blood cell analyzer from the collected whole blood samples. See Tables 2 and 3 for details.

[0088] Table 2 Hematological parameters on day 15

[0089] Table 3 Hematological parameters on day 30

[0090] As shown in Tables 2 and 3, on days 15 and 30 of the experiment, the hematological parameters of groups 1, 3 and 5 were all within the normal physiological range for cats compared with the control group.

[0091] Blood biochemical markers were measured in serum samples using a fully automated biochemical analyzer. As shown in Tables 4 and 5, the blood biochemical markers included alanine aminotransferase (ALT), aspartate aminotransferase (AST), fasting blood glucose (GLU), blood urea nitrogen (BUN), serum alkaline phosphatase (ALP), creatinine (Cr), total cholesterol (TCHO), total protein (TP), serum albumin (ALB), globulin (GLB), creatine kinase (CK), and lactate dehydrogenase (LHD). These markers were measured at 15 and 30 days of the experiment.

[0092] Table 4. Blood biochemical indicators on day 15

[0093] Table 5. Blood biochemical indicators on day 30

[0094] As shown in Tables 4 and 5, compared with the control group, the blood biochemical indicators in the treatment groups of Examples 1, 3, and 5 were all within the normal range for cats, indicating that the pet health products of the present invention have no negative impact on the liver and kidney function, as well as health indicators such as glucose and protein metabolism in cats. Blood electrolyte testing: Serum samples were analyzed for blood electrolyte levels using a Smart dry biochemical blood gas analyzer. As shown in Tables 6 and 7, blood electrolyte levels include potassium ions (K). + Sodium ions (Na) + ), chloride ions (Cl) - ), magnesium ions (Mg 2+ Inorganic phosphorus (P) + ), calcium ions (Ca 2+ Blood electrolyte levels, etc., were measured at 15 and 30 days of the trial.

[0095] Table 6 Blood electrolyte levels on day 15

[0096] Table 7 Blood electrolyte levels on day 30

[0097] As shown in Tables 6 and 7, compared with the control group, the blood electrolyte levels in the treatment groups of Examples 1, 3 and 5 were all within the normal range for cats. It was found that each electrolyte level was higher than that of the control group. This may be because the protein hydrolysate promotes the absorption of minerals, indicating that the pet health care product of the present invention has no negative impact on the blood electrolyte level of cats.

[0098] Fecal Stool Scoring: The Waltham Fecal Stool Scoring Scale (Table 8) was used for scoring. Professionals with basic pet care knowledge, capable of independently understanding the relationship between fecal characteristics and pet health, observed the shape of fresh feces and scored the stool. The results are shown in Tables 1-1, 1-2, and 1-3.

[0099] Table 8 Stool Scoring Criteria

[0100] As can be seen from Tables 1-1, 1-2 and 1-3, the fecal condition of cats in Examples 1, 3 and 5 remained good before and after the experiment, with no severe diarrhea or soft stools. This indicates that the pet health care product of the present invention has no negative impact on the digestion, fecal condition and intestinal health of cats.

[0101] Pet health products sensitization test The molecular weight distribution of protein hydrolysates was analyzed using high performance size exclusion chromatography (HPSEC), and the proportion of different molecular weight ranges in the protein hydrolysates was calculated. The proportion of peptides with a molecular weight of less than 1500 Da was given special attention. Theoretically, the smaller the molecular weight, the lower the probability of immune recognition. The results were compared with those of traditional commercially available products, and the results are shown in Table 9.

[0102] Table 9. Comparison of allergens and their molecular weights between this product and other commercially available products.

[0103] Twenty cats were recruited and divided into two groups of 10 each: an experimental group and a control group. All cats had no history of immune-mediated diseases or other diseases that could cause chronic gastrointestinal dysfunction, including liver disease, pancreatic insufficiency, metabolic diseases, parasitic diseases, and kidney diseases. The cats had not received any medications or diets related to the tested function within the past three months, had not used antibiotics, immunosuppressive drugs, or undergone surgery. Pregnant and lactating cats, and cats unable to eat orally, were excluded. The formulations from Examples 1, 3, and 5 were prepared and added directly to the cat's diet for the experimental group.

[0104] Experimental group: 10 cats per group were fed 2g of the formulas in Examples 1, 3, and 5 (containing 6mg of IgY antibody) per 2kg of body weight every other day for 60 consecutive days.

[0105] Control group: 30 adult cats were divided into 3 groups of 10 cats each, namely control group 1, control group 3 and control group 5. The control groups were all diets without the formulation of the example.

[0106] Saliva samples were collected from each cat for three consecutive days before feeding (Day 0 of the mixed sample test), and on days 29, 30, and 31 of the feeding process (Day 30 of the mixed sample test), and on days 59, 60, and 61 of the feeding process (Day 60 of the mixed sample test). The allergen content was detected by enzyme-linked immunosorbent assay (ELISA).

[0107] Tables 10-1, 10-2, and 10-3 represent the Feld1 test results before and after the experimental groups of the feeding examples (the results are shown as average values): Table 10-1 Feld1 content in cat saliva before and after the experiment in the experimental and control groups of Feeding Example 1

[0108] Table 10-2 Feld1 content in cat saliva before and after the experiment in the formula experimental group and control group of Feeding Example 3

[0109] Table 10-3 Feld1 content in cat saliva before and after the experiment in the experimental and control groups of Feeding Example 5

[0110] According to the above test results, when 2g of pet health supplement containing IgY antibody was mixed with 40g of daily food and fed for 60 days, the Feld1 allergen content in the control group did not change significantly before and after the experiment, while the Feld1 allergen content in the experimental group decreased by at least 60% compared with before the experiment.

[0111] The Feld4 and Feld7 allergen levels were detected using the same detection method. The Feld4 and Feld7 allergen levels in the control group showed no significant change before and after the experiment, while the Feld4 and Feld7 allergen levels in the experimental group decreased by at least 60% compared to before the experiment.

[0112] The pet health products involved in this invention effectively reduce allergens in pet cats through a convenient feeding method rather than injection, bringing great benefits to cat lovers and those prone to cat allergies.

[0113] Because feline allergy testing involves animal welfare and ethical considerations, we adopted Meng Zhipeng's method, "Cross-reactivity Study of Food Allergen Buffalo Milk β-Lactoglobulin," to prepare rabbit anti-TM (tropomyosin) polyclonal antibodies. Four healthy 8-week-old Japanese white rabbits were selected and fed an allergen-free diet. Immunization was performed via multiple intravenous injections. The allergenic protein TM was diluted with PBS (pH 7.0, 0.01 mol / L). For the initial immunization, an equal volume of Freund's complete adjuvant was used for emulsification, with an immunization dose of 2 mg / mL per rabbit. Booster immunizations were performed every 14 days, using Freund's incomplete adjuvant for emulsification, with an immunization dose of 0.5 mg / L per rabbit. After achieving the target titer, a large amount of blood was collected from the artery. After clotting at 37°C for 1 hour, the blood was incubated overnight at 4°C. Serum was separated (centrifuged at 4000 rpm for 3 min) and stored at -20°C for later use.

[0114] The method described by Han Jianxun, "Study on the Sensitization and Structural Changes of Pseudomyosin in Shrimp under High Hydrostatic Pressure Treatment," was modified, and the antigenicity of TM was assessed using ELISA. 100 μL of sample (2 μg / mL, diluted with coating buffer) was added to a 96-well microplate, with six replicates for each dilution, and coated overnight at 4°C. Then, 100 μL of blocking buffer containing 5% skim milk powder was added to each well, and the plate was blocked at 37°C for 2 hours. Next, 100 μL of rabbit anti-TM polyclonal antibody (diluted 100,000 times with PBST) was added, and the plate was incubated at 37°C for 1 hour. Finally, 100 μL of goat anti-rabbit IgG-HRP (diluted 3,000 times with PBST) was added, and the plate was incubated at 37°C for 1 hour. After each step, the plate was washed three times with PBST and patted dry. Finally, add 100 μL of TMB chromogenic solution, incubate in the dark for 10 min, then add 50 μL of 2 mol / L H2SO4 to terminate the reaction. Use a microplate reader (Multiskan™ FC, Thermo Scientific) to read the absorbance at 450 nm, and record it as the OD value. 450 The result is as follows Figure 1 As shown.

[0115] from Figure 1 It was found that the hydrolyzed protein could significantly reduce allergic reactions.

[0116] Pet health supplement palatability assessment To verify the palatability of pet health supplements, 20 healthy adult cats (of different breeds but of roughly the same weight) were selected for a palatability test, following methods commonly used in the field. The pet health supplement was evenly sprinkled onto the cat food in a food bowl, placed in an independent testing area, and the cats were allowed to eat independently. The number of cats consuming the supplement was observed and recorded (see Table 11 for details).

[0117] Table 11 Palatability Data Statistics

[0118] As shown in Table 11, the pet health products of the present invention have a feed intake rate of no less than 95%, which does not affect the normal feeding of pets and demonstrates good palatability.

[0119] Tests on the effects of pet health supplements on pet coat health Ten healthy cats of different breeds were selected (nine British Shorthairs and one Domestic Shorthair): they were dewormed and vaccinated. The test cats were fed basic cat food supplemented with the formula from Example 3. They were housed individually in cages and fed at fixed times and locations, from 4:00 PM to 8:30 AM the following day. During the test period, the cats were fed in their own individual cages and had free access to water and movement.

[0120] The amount of staple food fed was calculated according to the daily energy requirements of cats with reference to "Nutritional Requirements of Dogs and Cats". In Example 3, the feeding amount was 2g / 2kg body weight per cat per day, and the test period was 30 days in total, with a formal test period of 30 days.

[0121] Hair color difference measurement One day before the test and on the last day, the color difference value of the middle part of the back of each cat was measured using a colorimeter. Before measurement, the equipment was blank calibrated, the observation angle was 10°, the light source was D65, and the measuring aperture was 8mm. During measurement, the colorimeter's measuring aperture was placed close to the test cat's fur, and the test animal was in a lying position. The colorimeter read the luminance value L*, redness value a*, and yellowness value b*. The measurement was repeated three times, and the average value was retained to two significant figures. The saturation value C* was calculated as (a*² + b*²) * 0.5. The results are shown in Table 12. Note: Luminance, also known as lightness, represents the brightness or darkness of a color. The higher the luminance value, the brighter the color; the lower the luminance value, the darker the color. Saturation refers to the vividness of a color. The higher the saturation value, the more vivid the color; the lower the saturation value, the paler the color.

[0122] Table 12 Hair color difference measurement values

[0123] As shown in Table 12, after supplementing with the formula in Example 3, the redness value of the cats' fur was significantly improved, and the brightness, yellowness and color saturation values ​​showed an increasing trend.

[0124] Hair growth rate measurement At the start of the test, on the last day of the first month, 10 bristles were taken from the shaved area in the middle of the back of each cat, the length was measured, and the daily hair growth rate was calculated. The results were retained to 3 significant figures, as shown in Table 13.

[0125] Table 13 Hair growth rate measurement values

[0126] As shown in Table 13, the average hair growth rate of the 10 test cats over 33 days was 0.055 cm / d.

[0127] Hair fiber breaking strength and elongation One day before and on the last day of the test, bristles were taken from the same location on each cat to measure the breaking strength and elongation of the hair fibers. At least 10-20 sets of stable and valid data were collected from each cat's bristles, retaining two significant figures. The testing method followed GB / T 13835.5 Rabbit Hair Fiber Test Methods Part 5: Single Fiber Breaking Strength and Elongation at Break. The results are shown in Table 14.

[0128] Table 14 Measurement values ​​of hair growth rate

[0129] As shown in Table 14, the elongation and breaking strength of the cats' hair increased after supplementing with the formula in Example 3, and the difference before and after was extremely significant.

[0130] Skin moisture, oil, elasticity and pH One day before the test and on the last day, the skin moisture and oil content of the left and right ears were measured using a capacitive skin moisture meter. The measurement site was the exposed skin along the left and right ear margins of the test cats. During measurement, the probe of the skin moisture meter was in contact with the skin surface, and the measurement was repeated three times, with the average value taken. Results are expressed as a percentage and retained to two significant figures.

[0131] One day before the test and on the last day, the pH of the skin on the left and right ears of each cat was measured using an electrode-type pH meter. The pH meter was calibrated for acidity / alkalinity before measurement. The pH values ​​of the skin on both ears of the test cats were then measured, and data were recorded after the values ​​stabilized. The measurement was repeated three times, and the average value was taken, retaining two significant figures. The measurement results are as follows: Figure 2 As shown.

[0132] Depend on Figure 2 It was found that after supplementing with the formula in Example 3, the cats' pH level increased significantly, and there was a trend towards increased moisture and elasticity. After supplementing with the formula in Example 3, the redness value of the cats' fur significantly increased, and the brightness, yellowness, and color saturation values ​​also showed an increasing trend. Higher brightness values ​​indicate better fur luster and better animal health. Higher saturation values ​​represent higher color saturation; fur with high color saturation is more eye-catching and is also related to pet health. Furthermore, after 33 days of feeding, the average fur growth rate of the 10 test cats was 0.055 cm / day. The cats' fur elongation and breaking strength were significantly improved, enhancing fur toughness. Simultaneously, the pH level of the cats' fur increased significantly, and there was a trend towards increased moisture and elasticity. In conclusion, the formula in Example 3 can improve the skin condition and fur health of cats.

[0133] Tests on the joint protection function of pet health products Cats with a lameness clinical score greater than 1, selected through clinical examination, were randomly divided into a control group and an experimental group, with 10 cats in each group. The control group was fed a regular diet, while the experimental group was fed a regular diet plus the formula from Example 5. On days 0 and 42 of the experiment, body weight and Morton's clinical lameness score (out of 4) were measured; blood samples were collected to detect inflammatory markers.

[0134] Lameness score The condition of the cat's joints was scored according to the feline clinical lameness scoring criteria, as shown in Table 15.

[0135] Table 15 Clinical Lameness Scoring Criteria in Cats

[0136] The scoring results are as follows Figure 3 As shown.

[0137] like Figure 3 It can be seen that there was no significant difference in lameness scores between the control group and the experimental group before the experiment. After 42 days, although there was no significant difference between the control groups, the lameness scores of the control group at 42 days showed an increasing trend compared with those of the control group at 0 days. The lameness scores of the experimental group with joint care product intervention were significantly lower than those before the experiment.

[0138] X-ray and CT scans before and after the experiment The affected joints of the experimental cats were scanned using a Rigaku (Japan) pet-specific CT scanner. The scan results are as follows: Figure 4 As shown.

[0139] like Figure 4 It can be seen that an X-ray examination was performed on one cat in the experimental group (lame score 4) before the experiment. No obvious abnormalities were found in the shoulder joint. The lateral view of the hip joint showed that the left hip joint space was larger than normal, and the left femoral head was not fully covered in the anteroposterior view. The joint space was larger than normal. After the intervention with joint care products, a CT scan was performed. It was found that the left hip joint space did not continue to deteriorate, indicating that the joint care products can effectively relieve the symptoms of lame cats.

[0140] Effects on inflammatory markers The results of detecting inflammatory markers in cat blood using Luminex liquid chromatography-mass spectrometry are shown in Table 16.

[0141] Table 16 Measurement values ​​of feline blood validation indicators

[0142] As shown in Table 16, there were no significant differences in the levels of pro-inflammatory factors TNF-α, IL-6, and IL-8, and anti-inflammatory factors IL-2 and IL-10 between the control and experimental groups before the experiment. After 42 days, there were no significant differences in the levels of pro-inflammatory factors TNF-α, IL-6, and IL-8, and anti-inflammatory factors IL-2 and IL-10 between the control and experimental groups. However, in the experimental group, the levels of pro-inflammatory factors TNF-α, IL-6, and IL-8 showed a decreasing trend before and after the experiment, while the levels of anti-inflammatory factors IL-2 and IL-10 showed an increasing trend.

[0143] The above embodiments merely illustrate several implementation methods of this application, and while the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of this patent application. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of this application, and these all fall within the protection scope of this application. Therefore, the protection scope of this patent application should be determined by the appended claims.

Claims

1. A pet health product, characterized in that, Based on parts by weight, it includes the following raw material components: 60-90 parts of hydrolyzed small molecule protein peptides; Chicken egg-derived IgY antibody 0.1-1 part; 0.1 to 1 part of natural organic acids; 1-5 parts of glycerol; 0.1 to 1 part of natural antioxidants; Prebiotics 0.5-5 servings; 0-0.05 parts of ε-polylysine; Functional ingredients: 1-15 parts.

2. The pet health product as described in claim 1, characterized in that, The average molecular weight of the hydrolyzed small molecule protein peptides is 800 Da to 1500 Da; and / or, The functional ingredients include at least one of the following: polysaccharides, dietary fiber, polyphenols, functional lipids, minerals, vitamins, enzymes, plant active ingredients, peptides and proteins, and lactic acid bacteria.

3. The pet health product as described in claim 1, characterized in that, The chicken egg-derived IgY antibody is selected from egg yolk immunoglobulins produced after immunizing hens with Feld1 protein; and / or The natural organic acid is selected from at least one of malic acid, citric acid, lactic acid, and tartaric acid.

4. The pet health product as described in claim 1, characterized in that, The prebiotic is selected from at least one of liquid galactooligosaccharide, liquid fructooligosaccharide, liquid isomaltooligosaccharide, and liquid xylooligosaccharide; and / or, The natural antioxidant is selected from at least one of vitamin C and its derivatives, vitamin E and its derivatives, astaxanthin, and rosemary extract.

5. A method for preparing a pet health product as described in any one of claims 1 to 4, characterized in that, Includes the following steps: Hydrolyzed small molecule protein peptides, glycerol, prebiotics and natural organic acids are homogenized and emulsified in water to obtain the first material. The first material is sterilized to obtain the second material; At room temperature, natural antioxidants, chicken egg-derived IgY antibodies, ε-polylysine and functional ingredients are added to the second material and mixed well to obtain the third material. The third material is concentrated and molded under vacuum conditions at 55~60℃ to obtain a pet health product.

6. The method for preparing pet health products as described in claim 5, characterized in that, The homogenization emulsification temperature is 45℃~50℃; and / or, During emulsification, the rotation speed is between 3000 r / min and 10000 r / min.

7. The method for preparing pet health products as described in claim 5, characterized in that, The homogenization and emulsification process is performed at a frequency of once every 15 minutes of homogenization followed by vacuuming, and this process is repeated 2-5 times, with the number of vacuuming cycles being the same as the number of homogenization and emulsification cycles; and / or, The homogenization emulsification was carried out under conditions of -0.08 to -0.07 MPa.

8. The method for preparing pet health products as described in claim 5, characterized in that, The sterilization process is performed at a temperature of 90-95°C for 10-15 minutes; and / or, After the sterilization process, the temperature is lowered to 55~60℃.

9. The method for preparing pet health products as described in claim 5, characterized in that, The vacuum degree of the concentration process is -0.08 to -0.07 MPa; and / or, After concentration and molding, the moisture content of the product is 35-40%.

10. The use of a pet health product prepared by the method of preparing a pet health product according to any one of claims 1 to 4 or any one of claims 5 to 9 in the preparation of hypoallergenic pet products.

Images